Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Cash from Operations (2016 - 2025)

Historic Cash from Operations for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $562.1 million.

  • United Therapeutics' Cash from Operations rose 4901.91% to $562.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 3691.71%. This contributed to the annual value of $1.3 billion for FY2024, which is 3569.53% up from last year.
  • Per United Therapeutics' latest filing, its Cash from Operations stood at $562.1 million for Q3 2025, which was up 4901.91% from $191.7 million recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Cash from Operations registered a high of $562.1 million during Q3 2025, and its lowest value of $89.8 million during Q1 2021.
  • Moreover, its 5-year median value for Cash from Operations was $232.2 million (2024), whereas its average is $259.0 million.
  • As far as peak fluctuations go, United Therapeutics' Cash from Operations tumbled by 5815.47% in 2021, and later soared by 22149.22% in 2022.
  • United Therapeutics' Cash from Operations (Quarter) stood at $174.6 million in 2021, then fell by 26.58% to $128.2 million in 2022, then grew by 17.55% to $150.7 million in 2023, then skyrocketed by 126.41% to $341.2 million in 2024, then skyrocketed by 64.74% to $562.1 million in 2025.
  • Its last three reported values are $562.1 million in Q3 2025, $191.7 million for Q2 2025, and $461.2 million during Q1 2025.